300
Participants
Start Date
July 31, 2005
Primary Completion Date
April 30, 2012
Study Completion Date
December 31, 2013
ATRA
45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
Idarubicina
Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
Mitoxantrone
Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
ARA-C
In high risk patients, consolidation with ara-C in cycles 1 and 3.
PALG, Lodz
Hospital Juan Canalejo, A Coruña
Hospital General, Albacete
Hospital general, Alicante
Hospital germans Trias i Pujol, Badalona
Hospital Clinic, Barcelona
Hospital de Sant Pau, Barcelona
Institut Català d'Oncologái, Barcelona
Basurtuko Ospitalea, Bilbao
Hospital general, Castellon
Hospital de Fuenlabrada, Fuenlabrada
"Hospital Dr. Trueta", Girona
Hospital de Jerez de la Frontera, Jerez de la Frontera
Hospital Insular de las Palmas, Las Palmas de Gran Canaria
Complejo Hospitalario León, León
Complexo Hospitalario Xeral-Calde, Lugo
Hospital 12 de Octubre, Madrid
Hospital Clínico San Carlos, Madrid
Hospital Puerta de Hierro, Madrid
Hospital Reina Sofia, Madrid
Hospital San Pedro de Alcántara, Madrid
Hospital Severo Ochoa, Madrid
H. Carlos Haya, Málaga
H. Universitario Virgen de la Victoria, Málaga
Hospital Sta. Maria del Rosell, Murcia
Hospital Central de Asturias, Oviedo
Hospital Dr Negrín, Palma de Gran Canaria
Hospital de Navarra, Pamplona
Hospital de Montecelo, Pontevedra
Hospital Clínico Universitario, Salamanca
Hospital de Cruces, Santander
Hospital de Santiago de Compostela, Santiago de Compostela
H.U. Virgen del Rocio, Seville
Hospital Joan XXIII, Tarragona
Hospital Dr. Peset, Valencia
Hospital general, Valencia
Hospital La Fe, Valencia
Hospital Clínico de Valladolid, Valladolid
Hospital Txagorritxu, Vitoria-Gasteiz
Hospital Virgen de la Concha, Zamora
Hospital Clínico Universitario Lozano Blesa, Zaragoza
Hospital Maciel, Montevideo
PETHEMA Foundation
OTHER